| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Surrozen, Inc./DE | Former Director | Common Stock | 30K | $11.4K | $0.38 | Aug 11, 2021 | Direct |
| Elicio Therapeutics, Inc. | Title: Executive Vice President, Head of R&D and Chief Medical Officer | Stock Option (Right to Buy) | 28.2K | Sep 30, 2024 | Direct | ||
| Surrozen, Inc./DE | Former Director | Class B Ordinary Shares | 0 | Aug 11, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ELTX | Elicio Therapeutics, Inc. | Sep 30, 2024 | 1 | $0 | 4 | Oct 2, 2024 | Title: Executive Vice President, Head of R&D and Chief Medical Officer |
| ELTX | Elicio Therapeutics, Inc. | Feb 1, 2024 | 1 | $0 | 4 | Feb 5, 2024 | Title: Executive Vice President, Head of R&D and Chief Medical Officer |
| ELTX | Elicio Therapeutics, Inc. | Jun 1, 2023 | 0 | $0 | 3 | Jun 12, 2023 | Exhibit 24.1 - Power of Attorney. Title: Executive Vice President, Head of R&D and Chief Medical Officer |
| SRZN | Surrozen, Inc./DE | Aug 11, 2021 | 2 | $0 | 4 | Aug 13, 2021 | Former Director |